

## MARKED-UP CLAIM AMENDMENTS

1. (Amended) Method of treating an underlying cause of a pathological [conditions] condition characterized by an increased IL-1 and/or TNF- $\alpha$  level which comprises administering to a subject having such condition a therapeutically effective amount of at least one member selected from [the] a first group consisting of diacerein and rhein<sub>1</sub> in a pharmaceutical dosage form.

11. (Amended) Method of treating an underlying cause of an inflammatory [and] and/or autoimmune [conditions] condition characterized by an increased IL-1 [and or] and/or TNF- $\alpha$  level which comprises modifying the production or action of proinflammatory cytokines<sub>1</sub> including said IL-1 and/or TNF- $\alpha$ <sub>1</sub> by administering to a subject having such condition a therapeutically effective amount of at least one member selected from [the] a first group consisting of diacerein and rhein<sub>1</sub> in a pharmaceutical dosage form.

EX A